TOSUFLOXACIN TOSILATE manufacturers
- TOSUFLOXACIN TOSILATE
-
- $7.00 / 1KG
-
2020-02-12
- CAS:100490-36-6
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 100KG
|
| | TOSUFLOXACIN TOSILATE Basic information |
| Product Name: | TOSUFLOXACIN TOSILATE | | Synonyms: | 1,8-naphthyridine-3-carboxylicacid,1,4-dihydro-7-(3-amino-1-pyrrolidinyl)-1-(;4-difluorophenyl)-6-fluoro-4-oxo-;a61827;a67107;1-(2,4-Difluorophenyl)-6-fluoro-1,4-dihydro-7-(3-aminopyrrolidin-1-yl)-4-oxo-1,8-naphthyridine-3-carboxylic acid;1,8-Naphthyridine-3-carboxylic acid, 7-(3-amino-1-pyrrolidinyl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo- (9CI);A-60969;Ozex | | CAS: | 100490-36-6 | | MF: | C19H15F3N4O3 | | MW: | 404.34 | | EINECS: | | | Product Categories: | | | Mol File: | 100490-36-6.mol |  |
| | TOSUFLOXACIN TOSILATE Chemical Properties |
| Boiling point | 614.4±55.0 °C(Predicted) | | density | 1.558±0.06 g/cm3(Predicted) | | pka | 5.79±0.70(Predicted) | | InChI | InChI=1S/C19H15F3N4O3/c20-9-1-2-15(13(21)5-9)26-8-12(19(28)29)16(27)11-6-14(22)18(24-17(11)26)25-4-3-10(23)7-25/h1-2,5-6,8,10H,3-4,7,23H2,(H,28,29) | | InChIKey | WUWFMDMBOJLQIV-UHFFFAOYSA-N | | SMILES | N1(C2=CC=C(F)C=C2F)C2C(=CC(F)=C(N3CCC(N)C3)N=2)C(=O)C(C(O)=O)=C1 | | CAS DataBase Reference | 100490-36-6(CAS DataBase Reference) |
| | TOSUFLOXACIN TOSILATE Usage And Synthesis |
| Uses | Tosufloxacin Tosilate (CAS# 100490-36-6) was identified in a Haemophilus influenza clone ST422. | | Definition | ChEBI: 7-(3-aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid is a 1,8-naphthyridine derivative that is 4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid bearing additional 2,4-difluorophenyl, fluoro and 3-aminopyrrolidin-1-yl substituents at positions 1, 6 and 7 respectively. It is a 1,8-naphthyridine derivative, an amino acid, a monocarboxylic acid, an organofluorine compound, an aminopyrrolidine, a tertiary amino compound, a primary amino compound and a quinolone antibiotic. It is a conjugate base of a 1-[6-carboxy-8-(2,4-difluorophenyl)-3-fluoro-5-oxo-5,8-dihydro-1,8-naphthyridin-2-yl]pyrrolidin-3-aminium. | | in vivo | Tosufloxacin tosylate hydrate (T-3262) (oral gavage; 0.16-13.39 mg/kg; once) treatment shows antibacterial activity against S. aureus, E. coli, and P. aeruginosa in vivo[2]. | Animal Model: | Male Slc:ICR mice infected with S. aureus[2] | | Dosage: | 1.27-2.15 mg/kg | | Administration: | Oral gavage; 1.27-2.15 mg/kg; once | | Result: | Showed 50% effective dose (ED50) of 1.62 mg/kg (body weight) at 7 days after infection.
Showed MIC value of 0.0125 μg/mL. |
| Animal Model: | Male Slc:ICR mice infected with E. coli[2] | | Dosage: | 0.16-0.30 mg/kg | | Administration: | Oral gavage; 0.16-0.30 mg/kg; once | | Result: | Showed 50% effective dose (ED50) of 0.22 mg/kg (body weight) at 7 days after infection.
Showed MIC value of 0.0125 μg/mL. |
| Animal Model: | Male Slc:ICR mice infected with P. aeruginosa[2] | | Dosage: | 7.66-13.39 mg/kg | | Administration: | Oral gavage; 7.66-13.39 mg/kg; once | | Result: | Showed 50% effective dose (ED50) of 10.13 mg/kg (body weight) at 7 days after infection.
Showed MIC value of 0.78 μg/mL. |
| | IC 50 | Quinolone |
| | TOSUFLOXACIN TOSILATE Preparation Products And Raw materials |
|